Amgen To Present At The Goldman Sachs 42nd Annual Global Healthcare Conference

Rhea-AI Summary

Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, 2021, at 4:40 p.m. ET. Key executives, including David M. Reese and Peter H. Griffith, will speak at this event. A live audio broadcast of the presentation will be available for the public, and the replay will be accessible for 90 days post-event. Amgen, a leader in biotechnology since 1980, focuses on innovative therapeutics for serious illnesses, leveraging advanced human genetics to improve health outcomes.

THOUSAND OAKS, Calif., June 4, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 42nd Annual Global Healthcare Conference at 4:40 p.m. ET on Wednesday, June 9, 2021. David M. Reese, M.D., executive vice president of Research and Development and Peter H. Griffith, executive vice president and chief financial officer at Amgen will present at the conference. Live audio of the conference call will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given at certain investor and medical conferences, can be accessed on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

About Amgen 
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.  

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.  

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.  

CONTACT: Amgen, Thousand Oaks 
Megan Fox, 805-447-1423 (media)
Michael Strapazon, 805-313-5553 (media) 
Arvind Sood, 805-447-1060 (investors) 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/amgen-to-present-at-the-goldman-sachs-42nd-annual-global-healthcare-conference-301306277.html

SOURCE Amgen

FAQ

What time will Amgen present at the Goldman Sachs conference on June 9, 2021?

Amgen will present at 4:40 p.m. ET on June 9, 2021.

Who will represent Amgen at the Goldman Sachs 42nd Annual Global Healthcare Conference?

David M. Reese and Peter H. Griffith will represent Amgen at the conference.

How can I access the Amgen presentation at the Goldman Sachs conference?

The presentation will be available via live audio broadcast on Amgen's website.

Will the Amgen presentation be available for replay?

Yes, the webcast of the presentation will be archived for at least 90 days after the event.

What is Amgen's focus in biotechnology?

Amgen focuses on developing innovative therapeutics for serious illnesses using advanced human genetics.